valuation thoughts, page-86

It's impossible to know exactly without seeing all the data, which I suspect they will only provide snippets of... hopefully they are meaningful enough for us to make a 'call'.. but the way I look at it is that for a treatment to succeed you need to make 100 correct steps... and only one misstep to fail.

So whilst each step we take may not in itself be measurable as to its value, there is no doubt that each step we take in the right direction is getting us closer to realising its full potential... but with all biotechs, we are only one misstep away from failure.. which is why we can't attribute 'full value' to anything, until it is approved by the FDA. Up until then, my guess is as good as yours as to what valuation CHM should have All I can say is that it should be higher after these results, than before they were announced.